The Discounted Cash Flow (DCF) valuation of Intra-Cellular Therapies Inc (ITCI) is (609.35) USD. With the latest stock price at 131.87 USD, the upside of Intra-Cellular Therapies Inc based on DCF is -562.1%.
Based on the latest price of 131.87 USD and our DCF valuation, Intra-Cellular Therapies Inc (ITCI) is a sell. selling ITCI stocks now will result in a potential gain of 562.1%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 4.9% - 6.5% | 5.7% |
| Long-term Growth Rate | 3.0% - 4.7% | 3.8% |
| Fair Price | (4,492.16) - (328.30) | (609.35) |
| Upside | -3506.5% - -349.0% | -562.1% |